AMRX — Amneal Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723128 ·
Last close
$21.12
Market Cap
$7.36B
52W High
$22.07
52W Low
$11.39
ADV30
3,879,002
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 796,197,000 | 334,508,000 | 145,980,000 | 57,662,000 | 3,776,348,000 | 127,637,000 | 3,743,324,000 |
| Mar 2026 | 722,519,000 | 320,113,000 | 148,269,000 | 62,256,000 | 3,540,218,000 | 197,656,000 | 3,586,187,000 |
| Dec 2025 | 814,319,000 | 297,190,000 | 114,503,000 | 35,076,000 | 3,678,280,000 | 282,029,000 | 3,749,609,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$180,627,000
Investing CF
$-662,139,000
Financing CF
$425,371,000
CapEx
$-241,807,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.42
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-436,782,000
Inventory
$707,956,000
Receivables
$1,144,498,000
ST Investments
—
EBIT TTM
$445,012,000
Pretax Income TTM
$221,458,000
Interest Exp TTM
$223,554,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,195,718,912
EBITDA
$726,766,016
Free Cash Flow
$-45,125,624
Enterprise Value
$10,679,200,768
Total Cash
$162,211,008
Total Debt
$3,282,895,104
Shares Out
348,412,726
Trailing EPS
$0.40
Book Value
$1.52
ROE
70.0%
ROA
7.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,018,760,000 | 397,914,000 | 72,057,000 | 3,678,280,000 | 3,749,609,000 | -70,794,000 | 339,992,000 |
| Dec 2024 | 2,793,957,000 | 348,373,000 | -116,886,000 | 3,501,445,000 | 3,610,957,000 | -109,267,000 | 295,099,000 |
| Dec 2023 | 2,393,607,000 | 238,747,000 | -83,993,000 | 3,472,569,000 | 3,452,558,000 | 19,781,000 | 345,577,000 |
| Dec 2022 | 2,212,304,000 | 188,922,000 | -129,986,000 | 3,799,341,000 | 3,615,362,000 | 298,421,000 | 65,100,000 |
TTM Snapshot
Revenues TTM
$3,117,548,000
NetIncome TTM
$157,363,000
OpCashFlow TTM
—
Assets (Latest)
$3,776,348,000
Forward EPS
$1.23
Max Pain — expiry 2027-03-19
max pain strike: $20.00 · spot: $21.88 · call oi: 2,475 · put oi: 2,025
Expected Move to 2027-03-19:
±$6.25
(28.56%) —
implied range
$15.63 –
$28.13
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYTK | CYTOKINETICS INC | $7.20B | $51.65 | — |
| ABVX | Abivax S.A. | $7.16B | $82.10 | — |
| AXSM | Axsome Therapeutics, Inc. | $7.15B | $135.95 | — |
| ALKS | Alkermes plc. | $7.64B | $45.45 | — |
| CORT | CORCEPT THERAPEUTICS INC | $7.67B | $70.07 | — |
News headlines (Yahoo Finance, 1h cache)
Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
2026-11-18 16:34 · Yahoo
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
2026-11-18 15:35 · Yahoo
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
2026-11-17 21:05 · Yahoo
3 Insider Backed Growth Stocks With At Least 40% Earnings Growth
2026-11-17 18:10 · Yahoo
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
2026-11-17 15:11 · Yahoo
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
2026-11-16 16:13 · Yahoo
QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?
2026-11-13 17:16 · Yahoo
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
2026-11-13 15:41 · Yahoo
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
2026-11-13 13:20 · Yahoo
ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns
2026-11-13 11:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.